← Leaderboards
Rebecca L Aft
Washington University
$2,199,928
Attributed
$5,413,316
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $653.6K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,413,316 · 3
By mechanism
R01$5,153,248 · 2
R21$260,068 · 1
Top collaborators
- Mark A Watson10 shared
- David G Denardo5 shared
- Leonel Hernandez-Aya2 shared
Most similar at Washington University
Same institution · by research overlap
- David G Denardo$14,438,310
- James W Harbour$11,773,196
- Mark A Watson$16,564,971
- Ravindra Uppaluri$8,689,991
- David H Spencer$4,158,658
Others in their field
Top investigators on “Recurrence”
- Philip J Disaia · University Of California Irvine$95,481,777
- David Heimbrook · Leidos Biomedical Research, Inc.$87,033,539
- Wafaa M. El-Sadr · Columbia University Health Sciences$84,793,830
- Myron S Cohen · Family Health International$84,793,830
- Lawrence Corey · Fred Hutchinson Cancer Center$59,594,035
- Dan H. Barouch · Fred Hutchinson Cancer Center$59,594,035
Research focus
RecurrencePrimary NeoplasmPrognosticProspectiveMolecular ProfilingPathway InteractionsPhenotypeDetectionGenesMalignant Breast NeoplasmMolecularBone MarrowNeoplastic CellNeoplasm MetastasisBiologicalDistantBiological MarkersCohortGene ExpressionChemotherapyGene Expression ProfileCellsMetastatic ProcessResponse
Grant awards (12)
Synergized Immune and Tumor Cell Bone Marrow Biomarkers to Predict Recurrence in Triple Negative Breast Cancer$653,623
R01 · FY2025 · CA · contact PI
Synergized Immune and Tumor Cell Bone Marrow Biomarkers to Predict Recurrence in Triple Negative Breast Cancer$620,943
R01 · FY2024 · CA · contact PI
Synergized Immune and Tumor Cell Bone Marrow Biomarkers to Predict Recurrence in Triple Negative Breast Cancer$640,551
R01 · FY2023 · CA · contact PI
Synergized Immune and Tumor Cell Bone Marrow Biomarkers to Predict Recurrence in Triple Negative Breast Cancer$640,551
R01 · FY2022 · CA · contact PI
Synergized Immune and Tumor Cell Bone Marrow Biomarkers to Predict Recurrence in Triple Negative Breast Cancer$629,761
R01 · FY2021 · CA · contact PI
ANALYSIS AND THERAPEUTIC TARGETING OF BREAST CANCER DISSEMINATED TUMOR CELLS$384,803
R01 · FY2017 · CA · contact PI
ANALYSIS AND THERAPEUTIC TARGETING OF BREAST CANCER DISSEMINATED TUMOR CELLS$388,953
R01 · FY2016 · CA · contact PI
ANALYSIS AND THERAPEUTIC TARGETING OF BREAST CANCER DISSEMINATED TUMOR CELLS$392,520
R01 · FY2015 · CA · contact PI
ANALYSIS AND THERAPEUTIC TARGETING OF BREAST CANCER DISSEMINATED TUMOR CELLS$388,942
R01 · FY2014 · CA · contact PI
ANALYSIS AND THERAPEUTIC TARGETING OF BREAST CANCER DISSEMINATED TUMOR CELLS$412,601
R01 · FY2013 · CA · contact PI
Prognostic Marker Analysis of Disseminated Cancer Cells$128,488
R21 · FY2006 · CA · contact PI
Prognostic Marker Analysis of Disseminated Cancer Cells$131,580
R21 · FY2005 · CA